Oligometastases: Characterizing the Role of Epigenetic Regulation of Epithelial-Mesenchymal Transition

被引:4
作者
Katipally, Rohan R. [1 ]
Pitroda, Sean P. [1 ]
Weichselbaum, Ralph R. [1 ,2 ]
Hellman, Samuel [1 ]
机构
[1] Univ Chicago Med, Dept Radiat & Cellular Oncol, Chicago, IL USA
[2] Univ Chicago, Duchossois Ctr Adv Med, Dept Radiat Oncol, 5758 South Maryland Ave,MC 9006, Chicago, IL 60637 USA
关键词
CANCER; METASTASIS; CELLS; RESECTION; ZEB1; EMT;
D O I
10.1158/1078-0432.CCR-23-0376
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The "oligometastasis" hypothesis proposes that metastases exist as a spectrum and are not always disseminated. According to this theory, a subset of patients with metastatic disease could benefit from aggressive local therapies. However, the identifica-tion of patients most likely to exhibit an oligometastatic pheno-type remains challenging. Recent literature focusing on basic and translational studies has identified novel epigenetic regulators of epithelial-mesenchymal transition (EMT) and the emergence of a spectrum of metastatic behavior. Herein, we review these scientific advances and suggest that the spectrum of metastatic virulence produced by these epigenetic mechanisms broadly contributes to the emergence of clinically evident "oligometas-tases." Epigenetic regulation of EMT programs can result in a spectrum of cell trajectories (e.g., quasi-mesenchymal and highly mesenchymal states) with differential propensity to develop metastases. We propose that quasi-mesenchymal cell states may be associated with a polymetastatic phenotype, whereas highly mesenchymal cell states may be associated with a more oligometa-static phenotype. The mechanisms governing epigenetic regula-tion of EMT and its array of intermediate states are multifaceted and may contribute to the development of the metastatic spectrum observed clinically. Within this context, translational studies that support the role of EMT and its epigenetic regulation are dis-cussed. Continued translation of these mechanistic discoveries into novel biomarkers may help optimally select patients most likely to exhibit an oligometastatic phenotype and benefit from aggressive local therapies, such as surgery, radiotherapy, and other ablative
引用
收藏
页码:2761 / 2766
页数:6
相关论文
共 45 条
[1]   Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer [J].
Aghdassi, Ali ;
Sendler, Matthias ;
Guenther, Annett ;
Mayerle, Julia ;
Behn, Claas-Olsen ;
Heidecke, Claus-Dieter ;
Friess, Helmut ;
Buechler, Markus ;
Evert, Matthias ;
Lerch, Markus M. ;
Weiss, Frank Ulrich .
GUT, 2012, 61 (03) :439-448
[2]   An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non-Small-Cell Lung Cancer [J].
Ashworth, Allison B. ;
Senan, Suresh ;
Palma, David A. ;
Riquet, Marc ;
Ahn, Yong Chan ;
Ricardi, Umberto ;
Congedo, Maria T. ;
Gomez, Daniel R. ;
Wright, Gavin M. ;
Melloni, Giulio ;
Milano, Michael T. ;
Sole, Claudio V. ;
De Pas, Tommaso M. ;
Carter, Dennis L. ;
Warner, Andrew J. ;
Rodrigues, George B. .
CLINICAL LUNG CANCER, 2014, 15 (05) :346-355
[3]   Fsp1-Mediated Lineage Tracing Fails to Detect the Majority of Disseminating Cells Undergoing EMT [J].
Bornes, Laura ;
van Scheppingen, Roan Hugo ;
Beerling, Evelyne ;
Schelfhorst, Tim ;
Ellenbroek, Saskia Inge Johanna ;
Seinstra, Danielle ;
van Rheenen, Jacco .
CELL REPORTS, 2019, 29 (09) :2565-+
[4]   SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis [J].
Byles, V. ;
Zhu, L. ;
Lovaas, J. D. ;
Chmilewski, L. K. ;
Wang, J. ;
Faller, D. V. ;
Dai, Y. .
ONCOGENE, 2012, 31 (43) :4619-4629
[5]   New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer [J].
Dongre, Anushka ;
Weinberg, Robert A. .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2019, 20 (02) :69-84
[6]   Timeline - The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited [J].
Fidler, IJ .
NATURE REVIEWS CANCER, 2003, 3 (06) :453-458
[7]   Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance [J].
Fischer, Kari R. ;
Durrans, Anna ;
Lee, Sharrell ;
Sheng, Jianting ;
Li, Fuhai ;
Wong, Stephen T. C. ;
Choi, Hyejin ;
El Rayes, Tina ;
Ryu, Seongho ;
Troeger, Juliane ;
Schwabe, Robert F. ;
Vahdat, Linda T. ;
Altorki, Nasser K. ;
Mittal, Vivek ;
Gao, Dingcheng .
NATURE, 2015, 527 (7579) :472-+
[8]   Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer - Analysis of 1001 consecutive cases [J].
Fong, Y ;
Fortner, J ;
Sun, RL ;
Brennan, MF ;
Blumgart, LH .
ANNALS OF SURGERY, 1999, 230 (03) :309-318
[9]   Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study [J].
Gomez, Daniel R. ;
Blumenschein, George R., Jr. ;
Lee, J. Jack ;
Hernandez, Mike ;
Ye, Rong ;
Camidge, D. Ross ;
Doebele, Robert C. ;
Skoulidis, Ferdinandos ;
Gaspar, Laurie E. ;
Gibbons, Don L. ;
Karam, Jose A. ;
Kavanagh, Brian D. ;
Tang, Chad ;
Komaki, Ritsuko ;
Louie, Alexander V. ;
Palma, David A. ;
Tsao, Anne S. ;
Sepesi, Boris ;
William, William N. ;
Zhang, Jianjun ;
Shi, Qiuling ;
Wang, Xin Shelley ;
Swisher, Stephen G. ;
Heymach, John V. .
LANCET ONCOLOGY, 2016, 17 (12) :1672-1682
[10]   Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation [J].
Guckenberger, Matthias ;
Lievens, Yolande ;
Bouma, Angelique B. ;
Collette, Laurence ;
Dekker, Andre ;
deSouza, Nandita M. ;
Dingemans, Anne-Marie C. ;
Fournier, Beatrice ;
Hurkmans, Coen ;
Lecouvet, Frederic E. ;
Meattini, Icro ;
Romero, Alejandra Mendez ;
Ricardi, Umberto ;
Russell, Nicola S. ;
Schanne, Daniel H. ;
Scorsetti, Marta ;
Tombal, Bertrand ;
Verellen, Dirk ;
Verfaillie, Christine ;
Ost, Piet .
LANCET ONCOLOGY, 2020, 21 (01) :E18-E28